Effects of Curcumin on the Pharmacokinetics of Loratadine in Rats: Possible Role of CYP3A4 and P-glycoprotein Inhibition by Curcumin |
Li, Cheng
(College of Pharmacy, Chosun University)
Choi, Byung-Chul (Health Insurance Review and Assessment Service) Kim, Dong-Ki (College of Dentistry, Chosun University) Choi, Jun-Shik (College of Pharmacy, Chosun University) |
1 | Yumibe, N., Huie, K., Chen, K. J., Snow, M., Clement, R. P. and Cayen, M. N. (1996). Identifi cation of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochem. Pharmacol. 51, 165-172. DOI |
2 | Srivastava, K. C., Bordia, A. and Verma, S. K. (1995). Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanoid metabolism in human blood platelets. Prostaglandins. Leukot. Essent. Fatty Acids. 52, 223-227. DOI |
3 | Tanaka, T., Makita, H., Ohnishi, M., Hirose, Y., Wang, A., Mori, H., Satoh, K., Hara, A. and Ogawa, H. (1994). Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis by dietary curcumin and hesperidin: comparison with the protective effect of beta-carotene. Cancer Res. 54, 4653-4659. |
4 | Tarnasky, P. R. and Van Arsdel, P. P. Jr. (1990). Antihistamine therapy in allergic rhinitis. J. Fam. Prac. 30, 71-80. |
5 | Thapliyal, R. and Maru, G. B. (2001). Inhibition of cytochrome P450 isozymes by curcumins in vitro and in vivo. Food Chem. Toxicol. 39, 541-547. DOI |
6 | Wacher, V. J., Silverman, J. A., Zhang, Y. and Benet, L. Z. (1998). Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. 87, 1322-1330. DOI |
7 | Wang, E. J., Casciano, C. N., Clement, R. P. and Johnson, W. W. (2001). Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab. Dispos. 29, 1080-1083. |
8 | Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G. G. and Siegel, G. (2000). Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 10, 1439-1443. |
9 | Yin, O. Q., Shi, X. and Chow, M. S. (2003). Reliable and specifi c highperformance liquid chromatographic method for simultaneous determination of loratadine and its metabolite in human plasma. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 796, 165-172. DOI |
10 | Li, C., Kim, C. S., Yang, J. Y., Park, Y. J. and Choi, J. S. (2008). Effects of roxithromycin on the pharmacokinetics of loratadine after oral and intravenous administration of loratadine in rats. Eur. J. Drug Metab. Pharmacokinet. 33, 231-236. DOI |
11 | Philpot, E. E. (2000). Safety of second generation antihistamines. Allerg. Asthma. Proc. 21, 15-19. DOI |
12 | Pichard, L., Gillet, G., Fabre, I., Dalet-Beluche, I., Bonfi ls, C., Thenot, J. P. and Maurel, P. (1990). Identifi cation of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the Ndemethylation of diltiazem. Drug Metab. Dispos. 18, 711-719. |
13 | Shukla, P. K., Khanna, V. K., Ali, M. M. and Khan, M. Y. (2008). Anti-ischemic effect of curcumin in rat brain. Neurochem. Res. 33, 1036-1043. DOI |
14 | Prenner, B. M., Capano, D. and Harris, A. G. (2000). Efficacy and tolerability of loratadine versus fexofenadine in the treatment of seasonal allergic rhinitis: adouble-blind comparison with crossover treatment of nonresponders. Clin. Ther. 22, 760-769. DOI |
15 | Ramaekers, J. G., Uiterwijk, M. M. and O'Hanlon, J. F. (1992). Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving. Eur. J. Clin. Pharmacol. 42, 363-369. |
16 | Rao, C. V., Rivenson, A., Simi, B. and Reddy, B. S. (1995). Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res. 55, 259-266. |
17 | Singh, S. V., Hu, X., Srivastava, S. K., Singh, M., Xia, H., Orchard, J. L. and Zaren, H. A. (1998). Mechanism of inhibition of benzo[a] pyrene-induced forestomach cancer in mice by dietary curcumin. Carcinogenesis 19, 1357-1360. DOI |
18 | Singletary, K., MacDonald, C., Iovinelli, M., Fisher, C. and Wallig, M. (1998). Effect of the beta-diketones diferuloylmethane (curcumin) and dibenzoylmethane on rat mammary DNA adducts and tumors induced by 7,12-dimethylbenz[a]anthracene. Carcinogenesis 19, 1039-1043. DOI |
19 | Govindarajan, V. S. (1980). Turmeric--chemistry, technology, and quality. Crit. Rev. Food Sci. Nutr. 12, 199-301. DOI |
20 | Han, C. Y., Cho, K. B., Choi, H. S., Han, H. K. and Kang, K. W. (2008). Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. Carcinogenesis 29, 1837-1844. DOI |
21 | Ito, K., Kusuhara, H. and Sugiyama, Y. (1999). Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption; theoretical approach. Pharm. Res. 16, 225-231. DOI |
22 | Hilbert, J., Radwanski, E., Weglein, R., Luc, V., Perentesis, G., Symchowicz, S. and Zampaglione, N. (1987). Pharmacokinetics and dose proportionality of loratadine. J. Clin. Pharmacol. 27, 694-698. DOI |
23 | Huang, M. T., Lou, Y. R., Ma, W., Newmark, H. L., Reuhl, K. R. and Conney, A. H. (1994). Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res. 54, 5841-5847. |
24 | Huang, M. T., Newmark, H. L. and Frenkel, K. (1997). Inhibitory effects of curcumin on tumorigenesis in mice. J. Cell Biochem. 27, 26-34. |
25 | Kaminsky, L. S. and Fasco, M. J. (1991). Small intestinal cytochromes P450. Crit. Rev. Toxicol. 21, 407-422. |
26 | Kay, G. G., Berman, B., Mockoviak, S. H., Morris, C. E., Reeves, D., Starbuck, V., Sukenik, E. and Harris, A. G. (1997). Initial and steady-state effects of diphenhydramine and loratadine on sedation, cognition, mood, and psychomotor performance. Arch. Intern. Med. 57, 2350-2356. |
27 | Kelly, P. A., Wang, H., Napoli, K. L., Kahan, B. D. and Strobel, H. W. (1999). Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4. Eur. J. Drug. Metab. Pharmacokinet. 24, 321-328. DOI |
28 | Kosoglou, T., Salfi , M., Lim, J. M., Batra, V. K., Cayen, M. N. and Affrime, M. B. (2000). Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazole or cimetidine. Br. J. Clin. Pharmacol. 50, 581-589. |
29 | Cao, X., Gibbs, S. T., Fang, L., Miller, H. A., Landowski, C. P., Shin, H. C., Lennernas, H., Zhong, Y., Amidon, G. L., Yu, L. X. and Sun, D. (2006). Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res. 23, 1675-1686. DOI |
30 | Carr, R. A., Edmonds, A., Shi, H., Locke, C. S., Gustavson, L. E., Craft, J. C., Harris, S. I. and Palmer, R. (1998). Steady-State Pharmacokinetics and Electrocardiographic Pharmacodynamics of Clarithromycin and Loratadine after Individual or Concomitant Administration. Antimicrob. Agents. Chemother. 42, 1176-1180. |
31 | Choi, H., Chun, Y. S., Kim, S. W., Kim, M. S. and Park, J. W. (2006). Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. Mol. Pharm. 70, 1664-1671. DOI |
32 | Clissold, S. P., Sorkin, E. M. and Goa, K. L. (1989). Loratadine, a preliminary review of its pharmacodynamic properties and therapeutic effi cacy. Drugs 37, 42-57. |
33 | Crespi, C. L., Miller, V. P. and Penman, B. W. (1997). Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem. 248, 188-190. DOI |
34 | Cummins, C. L., Jacobsen, W. and Benet, L. Z. (2002). Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther. 300, 1036-1045. DOI |
35 | Deshpande, S. S., Ingle, A. D. and Maru, G. B. (1998). Chemopreventive effi cacy of curcumin-free aqueous turmeric extract in 7, 12-dimethylbenz [a] anthracene-induced rat mammary tumorigenesis. Cancer Lett. 123, 35-40. DOI ScienceOn |
36 | Efferth, T., Davey, M., Olbrich, A., Rücker, G., Gebhart, E. and Davey, R. (2002). Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrugresistant human CCRF-CEM leukemia cells. Blood Cells Mol. Dis. 28, 160-168. DOI |
37 | Bradley, C. M. and Nicholson, A. N. (1987). Studies on the central effects of the H1-antagonist, loratadine. Eur. J. Clin. Pharmacol. 32, 419-421. DOI |
38 | Aggarwal, B. B. and Shishodia, S. (2006). Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharm. 71, 1397-1421. DOI |
39 | Amini, H. and Ahmadiani, A. (2004). Rapid determination of loratadine in small volume plasma samples by high-performance liquid chromatography with fl uorescence detection. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 809, 227-230. DOI |
40 | Appiah-Opong, R., de Esch, I., Commandeur, J. N., Andarini, M. and Vermeulen, N. P. (2008). Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. Eur. J. Med. Chem. 43, 1621-1631. DOI |